Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standardof care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+),well-differentiated gastro-enteropancreatic